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With great interest we have read the article by Kim and
colleagues in this journal,1 demonstrating that intramuscular
administration of human umbilical cord blood mononuclear cells
(HCB-MNCs) enhances the number of capillaries, angiogenic gene
expression and angiogenic factors in a canine hind limb ischemia
model. We laud the attempt of the authors to translate their results
into clinical practice, administering HCB-MNCs in patients with
peripheral arterial occlusive disease (PAOD). However, this study
raises some important questions.
The authors put much emphasis on the potential development
of graft-versus-host disease (GVHD). GVHD is known to occur after
allogeneic stem cell transplantations, where donor lymphocytes
encounter and offend the (immunodeﬁcient) host’s tissues, and
has been reported as unusual adverse event after solid organ trans-
plantations and blood transfusions,2,3 always in states with impair-
ment of the recipient’s immune system. The article by Kim et al.
however reports on intramuscular allogeneic HCB-MNC adminis-
tration in fully immunocompetent individuals. The likelihood of
developing a GVHD-like phenomenon in this setting is low, since
donor derived allogeneic cells are delivered in a hostile environ-
ment with an active immune system. Induction of a widespread
immunogenic reaction comparable to GVHD is therefore nearly
impossible in our view. Rather, the recipient’s immune response
may lead to an inﬂammatory response and rapid removal of the
infused cells, which may limit the potential therapeutic effect of
allogeneic HCB-MNC. In that respect it is unfortunate that the
authors do not provide any efﬁcacy data from their clinical study.
Although we agree that, to assess the ultimate efﬁcacy of stem
cell therapy, objective criteria and larger series aremandatory, eval-
uation of previous studies on autologous progenitor cell safety and
efﬁcacy in small series of patients with thromboangiitis obliter-
ans4,5 were able to show signiﬁcant improvement of clinical param-
eters, such as transcutaneous oxygen pressure, pain, skin
temperature and ulcer healing. Presentation of such efﬁcacy data
for allogeneic HCB-MNC would be a valuable addition to this paper.
Altogether the authors propose an interesting therapeutic
strategy for PAOD patients, however, as autologous approaches
have already been shown promising and circumvent immunogenic
complexities, we advocate the autologous approach and further
improvement of these strategies.DOI of original article: 10.1016/j.ejvs.2012.01.009.References
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